This webinar will update and inform the nuclear medicine community of the current status and future outlook for the supply of Moly-99 and Tech-99. Panelists will provide publicly available information on their companies’ activities to support a reliable and sustainable supply of Mo-99 for patients now and well into the future. Potential future Mo-99 producers will provide publicly available information to update attendees on their respective projects. This webinar is intended for nuclear medicine physicians, technologists, pharmacists, and physicists.
Course Learning Objectives
- Provide attendees with an updated outlook on current and future supply of Molybdenum-99 (Mo-99).
- Inform attendees on publicly available industry activities and project
Roy Brown, BS, MBA
Vice President, Government Affairs & Strategic Alliances
Vice President and General Manager
BWXT Isotope Technologies
Ira Goldman, BA, MA
Senior Director, Global Strategic Supply and Government Relations
Lantheus Medical Imaging
Michael Guastella, MS, MBA
Council on Radionuclides and Radiopharmaceuticals, Inc.
James Harvey, PhD
Chief Science Officer
NorthStar Medical Technologies
Vice President, Pharmacy Safety, Practice & Tech. Ops.
Cardinal Health Nuclear & Precision Health Solutions
Greg Piefer, PhD
CEO and Founder
SHINE Medical Technologies
J. David Robertson, PhD
University of Missouri Research Reactor (MURR)
Interim President Jubilant Radiopharma
Chief Operating Officer
Eden Radioisotopes, LLC